Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Who May Qualify: - Participants who have pathologically confirmed adenocarcinoma of the prostate with formalin-fixed paraffin embedded (FFPE) biopsy tissue available for analysis, including those on active surveillance. Most recent biopsy can be any time in the six months prior to registration/randomization - Participants \>= 18 years will be enrolled. Because no dosing or adverse event (AE) data are currently available on the use of urolithin A in participants \< 18 years of age, children and adolescents are excluded from this study - Human weakened immune system virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial - For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Participants on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible - Scheduled to undergo RP in the next 3-6 weeks - Ability to understand and the willingness to sign a written willing to sign a consent form document Who Should NOT Join This Trial: - Participants with prior primary treatment or hormonal therapy for prostate cancer (PC) - Participants with documented active alcohol and illegal substance dependency - Participants already receiving urolithin A (Mitopure, commercially available in the United States), or pomegranate supplements. Note: Other supplements are allowed but must be documented - Participants receiving any other investigational agents - History of allergic reactions attributed to compounds of similar chemical or biologic composition to urolithin A ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.